Company Overview
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.11.
Recent Developments
- Dec 2025 Revenue of $2.04M (-67.3% YoY); net profit $-162.34M.
- Trailing 12 Months Year-on-year growth — revenue -60.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -60.20% |
Stock Price Performance
| 1 Year: | +398.80% |
| 6 Months: | +155.39% |
| 3 Months: | +5.27% |
| 1 Month: | +21.74% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)61.63 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DNTH Dianthus Therapeutics, Inc. R2K | 99.91 | -23.02 | $5.46B | 0.00% | -35.57% | -22.70% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.17M | - | - | 924.00K | 874.00K | 1.86M | 2.17M | 1.16M | 193.00K | 396.00K | - |
| Operating Income | -4.81M | -15.73M | -7.01M | -8.17M | -11.31M | -14.03M | -16.70M | -17.93M | -16.35M | -19.34M | -22.64M | -24.64M | -21.24M | -20.01M | -18.38M | -18.70M | -17.61M | -18.25M | -23.83M | -18.08M | -8.25M | -7.68M | -11.78M | -15.76M | -17.84M | -22.20M | -29.90M | -33.18M | -34.93M | -40.29M | -46.53M |
| Net Income | -4.81M | -15.73M | -6.91M | -8.04M | -11.16M | -13.66M | -16.02M | -16.68M | -14.83M | -17.71M | -20.99M | -23.24M | -20.01M | -19.08M | -17.68M | -17.49M | -16.93M | -17.43M | -4.88M | -5.70M | -7.78M | -7.09M | -11.14M | -14.76M | -13.75M | -17.61M | -25.17M | -29.51M | -31.63M | -36.77M | -40.83M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.36 | -0.32 | -0.30 | -0.39 | -0.29 | -8.90 | -8.10 | -12.73 | -3.78 | -0.54 | -0.51 | -0.74 | -0.82 | -0.88 | -0.97 | -0.85 |
| R&D Expense | - | 13.82M | 5.21M | - | 7.85M | 9.68M | 11.42M | - | 10.54M | 13.43M | 16.52M | - | 13.96M | 12.61M | 11.79M | 11.73M | 11.13M | 10.79M | 16.55M | 11.60M | 7.22M | 5.85M | 10.25M | 7.96M | 13.08M | 18.07M | 25.54M | 27.00M | 26.25M | 32.49M | 34.53M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | - | - | - | 2.83M | 6.24M | 2.04M |
| Operating Income | -9.27M | -35.73M | -59.96M | -82.97M | -78.70M | -74.69M | -29.70M | -48.17M | -101.86M | -177.93M |
| Net Income | -9.43M | -35.49M | -57.52M | -76.77M | -74.94M | -71.14M | -28.48M | -43.55M | -84.97M | -162.34M |
| Diluted EPS | - | - | - | - | -1.71 | -1.29 | -32.57 | -8.45 | -2.55 | -4.20 |
| R&D Expense | 5.78M | 27.90M | 41.34M | 59.21M | 50.62M | 46.77M | 29.38M | 32.84M | 83.11M | 145.64M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 54.46M | 157.31M | 161.51M | 161.62M | 189.93M | 83.11M | 179.41M | 374.01M | 530.92M |
| Total Equity | -289.00K | -8.87M | -42.12M | 145.65M | 141.19M | 143.91M | -17.25M | -44.37M | 168.87M | 352.48M | 493.40M |
| Cash & Equivalents | - | - | 51.40M | 58.34M | 65.07M | 58.15M | 131.65M | 15.37M | 132.32M | 22.79M | 51.09M |
| Total Liabilities | - | - | 4.14M | 11.66M | 20.32M | 17.71M | 17.26M | 9.45M | 10.54M | 21.53M | 37.52M |
| Current Liabilities | - | - | 4.14M | 10.42M | 14.12M | 11.43M | 10.86M | 8.22M | 9.63M | 18.45M | 30.73M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -6.53M | -22.26M | -41.89M | -57.10M | -64.02M | - | -29.07M | -36.86M | -78.18M | -129.06M |
| Investing Cash Flow | -139.00K | -2.20M | -91.70M | 1.53M | -10.63M | - | -59.82M | 20.25M | -286.81M | -122.83M |
| Financing Cash Flow | 10.71M | 71.49M | 142.15M | 62.30M | 67.74M | - | 96.68M | 133.57M | 255.62M | 280.12M |
| Capital Expenditure | -139.00K | -2.20M | -7.67M | -3.06M | -400.00K | - | -139.00K | -110.00K | -105.00K | -213.00K |
| Free Cash Flow | -6.67M | -24.46M | -49.56M | -60.16M | -64.42M | - | -29.21M | -36.97M | -78.28M | -129.27M |
| Net Change in Cash | - | - | - | - | - | - | 7.79M | 116.97M | -109.37M | 28.23M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | -1,704.7% | -1,633.7% | -8,739.3% |
| Net Margin % | - | - | - | - | - | - | - | -1,541.2% | -1,362.8% | -7,973.3% |
| ROE % | 106.3% | 84.3% | -39.5% | -54.4% | -52.1% | 412.4% | 64.2% | -25.8% | -24.1% | -32.9% |
| ROCE % | - | -71.0% | -40.8% | -56.3% | -52.4% | -41.7% | -39.7% | -28.4% | -28.6% | -35.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.21% | 7.77M | $786.71M |
| 2 | Blackrock Inc. | 5.81% | 3.18M | $321.64M |
| 3 | RA Capital Management, L.P. | 4.78% | 2.61M | $264.52M |
| 4 | Wellington Management Group, LLP | 4.75% | 2.60M | $262.90M |
| 5 | Fairmount Funds Management LLC | 4.64% | 2.54M | $256.97M |
| 6 | Avidity Partners Management, LP | 3.85% | 2.10M | $213.11M |
| 7 | Vanguard Capital Management LLC | 3.72% | 2.03M | $205.72M |
| 8 | Octagon Capital Advisors LP | 3.56% | 1.95M | $197.16M |
| 9 | TCG Crossover Management, LLC | 3.07% | 1.68M | $169.81M |
| 10 | Citadel Advisors Llc | 2.95% | 1.61M | $163.11M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DNTH
[Form 4] Dianthus Therapeutics, Inc. /DE/ Insider Trading Activity - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNT2lkM2oyb3RyR2pUYzRvd2l5d3BFd1BpZ3B6ZTlUVmh2OHlLM1NlandpdmFHc296SlFMcndXZUlfeWhWamxBelA5RXNFeER4eGI5TmFMQ2hrS3VndUZFQTdNU0hpbUlVX3NYTW02SVBNZVpVUk1qb085T0xwTW9PcTltOFlWUWtFaFNWTG…
(DNTH) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPN19MRm1leWhKQ3h0c0NadE9raGNEV29vT3dJWUVPTWY0SW9Ocmhoak9MclBWUzhQRTVpZUZFeWl0R3k4SjVyWC1OM0VhZlRhN2NUT0ZDcXNQMlVlVXFhYUJDdTNDNFR2TW9pSFY3TjEwVTljWjlUN3NwWk9vNnAybGtRWlMzbGRZSUZtRl…
Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxOaUZQbURjZmFQVVphYUhBLWpsU1I5TVRSUW8wOVgzV3kwYThyT2g0WVdZVS1pamtKWkdhRVpGMHYyWnZDRVZLYUhjUjRiamJNTkFLWUNSclUyVmJzRGpSWHMwLW05WG9BSEtZWHQ3WktPeGMtbTd0eFdsWEg1WkdEQ1BEX2YzcnRXemc?oc…
Dianthus Therapeutics (DNTH) Starts Phase 3 EMERGE Trial, Is The Upside Already Priced In? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxQTkh5MmY0VVhFQVlJTzV0TExZV1owZkxnVndITWo2N1k4RVJDY1BPZmg4c0c3cFk0SGw5aE5saUpwdVpHeWhFYzVZUVlueTVwWTRJZXNNbUh1QW5JM2dORkd3TGhFQVZhVjU2Y0VfSzBQWHBqbG9uSHVJZ01uNEgzV2JNVjZnazRfSU52SU…
$DNTH stock is down 15% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOXzlRdEhQRHJHS1NNZlVtV0xvX285cU1HT1pJRnF0cHNiN1JTYXJvRnVmVGFrV0xsanNqc2ZvS0tXV0ZyQWpCdGlCWnphQWk3amtTZERIeDFrdEdwaWRFTkg0UDNuZTQwcHVRMW1iV1ZkcDdTZ2tMcVJfUld3Nm94aEFmNHdTX3pQRFBEVD…
Why is Dianthus Therapeutics stock plunging today? - Investing.com
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPMlYxTVR2dHhDSVhxd0xjQV84NUFob1NDWXpHYlZPX1hlZ2xRYW50eW01QkJTYXNYekdVTUxZX2phZ3EyQUEyWE5sWl9pcjlYUDFUTmE3Nkp1STJmRE5xMHBWWnZZalZBeVBRS0hDQTdPTEVfRll3RmhJTnJScE9WanJVZUhFcHRyT0dRWl…
DNTH — Frequently Asked Questions
What is the current share price of Dianthus Therapeutics, Inc. (DNTH)?
As of 2026-07-15 16:51 PDT, Dianthus Therapeutics, Inc. (DNTH) trades at $99.91 on NasdaqCM. Its 52-week range is $18.76 to $101.28.
What is the market capitalisation of DNTH?
Dianthus Therapeutics, Inc. (DNTH) has a market capitalisation of $5.46B on NasdaqCM.
What is the P/E ratio of DNTH?
DNTH trades at a trailing price-to-earnings (P/E) ratio of -23.02. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 4.60.
What is the return on equity (ROE) of DNTH?
DNTH has a return on equity (ROE) of -22.70%. Its return on capital employed (ROCE) is -35.57%.
Is DNTH a good stock to buy?
This page provides a data-driven analysis of Dianthus Therapeutics, Inc. (DNTH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.